The results of Phase I studies are expected to be available in April 2009. Based on these and other results, Avineuro Pharmaceuticals plans to advance AVN-211 into Phase II clinical trials in the second quarter of 2009.
The results of Phase I studies are expected to be available in April 2009. Based on these and other results, Avineuro Pharmaceuticals plans to advance AVN-211 into Phase II clinical trials in the second quarter of 2009.